JP2021521193A - 虚血および心筋症の処置のための組成物および方法 - Google Patents

虚血および心筋症の処置のための組成物および方法 Download PDF

Info

Publication number
JP2021521193A
JP2021521193A JP2020555841A JP2020555841A JP2021521193A JP 2021521193 A JP2021521193 A JP 2021521193A JP 2020555841 A JP2020555841 A JP 2020555841A JP 2020555841 A JP2020555841 A JP 2020555841A JP 2021521193 A JP2021521193 A JP 2021521193A
Authority
JP
Japan
Prior art keywords
cells
stem cell
cell
polypeptide
camkk1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020555841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521193A5 (https=
Inventor
マーク エス． ペン，
マーク エス． ペン，
マリッツァ マヨルガ，
マリッツァ マヨルガ，
マシュー キードロウスキ，
マシュー キードロウスキ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northeast Ohio Medical University
Summa Health Systems LLC
Original Assignee
Northeast Ohio Medical University
Summa Health Systems LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northeast Ohio Medical University, Summa Health Systems LLC filed Critical Northeast Ohio Medical University
Publication of JP2021521193A publication Critical patent/JP2021521193A/ja
Publication of JP2021521193A5 publication Critical patent/JP2021521193A5/ja
Priority to JP2024196696A priority Critical patent/JP2025015574A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11017—Ca2+/Calmodulin-dependent protein kinase (2.7.11.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
JP2020555841A 2018-04-18 2019-04-17 虚血および心筋症の処置のための組成物および方法 Pending JP2021521193A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024196696A JP2025015574A (ja) 2018-04-18 2024-11-11 虚血および心筋症の処置のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659667P 2018-04-18 2018-04-18
US62/659,667 2018-04-18
PCT/US2019/027967 WO2019204509A2 (en) 2018-04-18 2019-04-17 Compositions and methods for the treatment of ischemia and cardiomyopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024196696A Division JP2025015574A (ja) 2018-04-18 2024-11-11 虚血および心筋症の処置のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2021521193A true JP2021521193A (ja) 2021-08-26
JP2021521193A5 JP2021521193A5 (https=) 2022-04-06

Family

ID=68240639

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020555841A Pending JP2021521193A (ja) 2018-04-18 2019-04-17 虚血および心筋症の処置のための組成物および方法
JP2024196696A Pending JP2025015574A (ja) 2018-04-18 2024-11-11 虚血および心筋症の処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024196696A Pending JP2025015574A (ja) 2018-04-18 2024-11-11 虚血および心筋症の処置のための組成物および方法

Country Status (5)

Country Link
US (2) US20210113662A1 (https=)
EP (2) EP3781182A4 (https=)
JP (2) JP2021521193A (https=)
IL (1) IL277773B1 (https=)
WO (1) WO2019204509A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025015574A (ja) * 2018-04-18 2025-01-30 スンマ ヘルス 虚血および心筋症の処置のための組成物および方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016029095A (ja) * 2009-10-23 2016-03-03 アモーサイト インコーポレイテッド 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2018502838A (ja) * 2014-12-01 2018-02-01 スンマ ヘルスＳｕｍｍａ Ｈｅａｌｔｈ 新規の再生治療剤としてのｃａｍｋｋ１

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US707993A (en) 1901-05-16 1902-08-26 Clinton J Warren Machine for corking bottles.
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US6852508B1 (en) * 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US20020107195A1 (en) * 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
US6103255A (en) 1999-04-16 2000-08-15 Rutgers, The State University Porous polymer scaffolds for tissue engineering
WO2002024920A2 (en) * 2000-09-19 2002-03-28 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
IL157335A0 (en) 2001-03-13 2004-02-19 Novartis Ag Lentiviral packaging constructs
DE10132440A1 (de) 2001-07-04 2003-01-23 Bosch Gmbh Robert System und Verfahren zum Überwachen des Fahrverhaltens eines Fahrzeugs
US20050271639A1 (en) 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US6993406B1 (en) 2003-04-24 2006-01-31 Sandia Corporation Method for making a bio-compatible scaffold
ATE388223T1 (de) 2003-10-29 2008-03-15 Fcb Pharmicell Co Ltd Verfahren zur differenzierung einer mesenchym- stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit
WO2006124013A2 (en) * 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
KR20070085288A (ko) * 2004-09-24 2007-08-27 안지오블라스트 시스템스 인코퍼레이티드 간엽 전구세포의 증식 및/또는 생존성 증강 방법
EP2465924A3 (en) 2005-06-16 2013-01-02 Ramot at Tel-Aviv University Ltd. Isolated cells and populations comprising same for the treament of cns diseases
WO2011026041A2 (en) * 2009-08-28 2011-03-03 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
US20130253035A1 (en) * 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
GB201303666D0 (en) 2013-03-01 2013-04-17 Goldsborough Andrew S Sample fixation and stabilisation
EP3039124A1 (en) * 2013-08-29 2016-07-06 Stempeutics Research Private Limited Stromal cells derived conditioned medium, method of obtaining said conditioned medium compositions, formulations and applications thereof
WO2015168145A1 (en) * 2014-04-28 2015-11-05 Penn Marc S Sdf-1 delivery for treating advanced ischemic cardiomyopathy
JP6797803B2 (ja) * 2014-12-31 2020-12-09 セルジーン コーポレイション ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法
EP3781182A4 (en) * 2018-04-18 2021-11-17 Summa Health COMPOSITIONS AND METHODS OF TREATMENT OF ISCHEMIA AND CARDIOMYOPATHIA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016029095A (ja) * 2009-10-23 2016-03-03 アモーサイト インコーポレイテッド 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2018502838A (ja) * 2014-12-01 2018-02-01 スンマ ヘルスＳｕｍｍａ Ｈｅａｌｔｈ 新規の再生治療剤としてのｃａｍｋｋ１

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CYTOTHERAPY, vol. 18, JPN6023016401, 2016, pages 13 - 24, ISSN: 0005569149 *
INT. J. MOL. MED., vol. 40, JPN6025014545, 2017, pages 418 - 426, ISSN: 0005569151 *
STEM CELLS INT., vol. 2015, JPN6025014546, 2015, pages 659890, ISSN: 0005569152 *
STEM CELLS TRANSL. MED., vol. 7, JPN6025014544, 2017, pages 115 - 124, ISSN: 0005569150 *
STEM CELLS TRANSLATIONAL MEDICINE, vol. 5, JPN6023016405, 2016, pages 1620 - 1630, ISSN: 0005569148 *
STEM CELLS TRANSLATIONAL MEDICINE, vol. 6, JPN6023016402, 2017, pages 1759 - 1766, ISSN: 0005569147 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025015574A (ja) * 2018-04-18 2025-01-30 スンマ ヘルス 虚血および心筋症の処置のための組成物および方法

Also Published As

Publication number Publication date
IL277773B1 (en) 2026-01-01
IL277773A (en) 2020-11-30
US20240082357A1 (en) 2024-03-14
WO2019204509A2 (en) 2019-10-24
EP4700117A3 (en) 2026-03-25
EP3781182A4 (en) 2021-11-17
WO2019204509A3 (en) 2019-12-05
EP4700117A2 (en) 2026-02-25
JP2025015574A (ja) 2025-01-30
EP3781182A2 (en) 2021-02-24
US20210113662A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
JP4280708B2 (ja) 虚血性心筋症において幹細胞のホーミングおよび組織再生を仲介するストローマ細胞由来因子−１（ｓｄｆ−１）
Zhang et al. Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium
AU2008260651B2 (en) CD34 stem cell-related methods and compositions
US20240425878A1 (en) Genetically modified msc and therapeutic methods
KR20250005439A (ko) 전신 면역억제가 불필요한 동종 이식편 내성
US20100119490A1 (en) Therapeutic Use of CD31 Expressing Cells
JP2010523496A (ja) 虚血障害の治療方法
JP2012100670A (ja) 幹細胞をホーミングさせるためのｃｃｒリガンド
JP2025015574A (ja) 虚血および心筋症の処置のための組成物および方法
CN114615985A (zh) 包含修饰mRNA的分子的组合物及其使用方法
WO2014035433A1 (en) Genetically modified msc and therapeutic methods
US20240254510A1 (en) Methods for generating mechanically-responsive cells and uses thereof
조현민 Therapeutic Effects of Genome-edited Mesenchymal Stem Cells Expressing VEGF and LEF1 on Myocardial Infarction
WO2025060840A1 (zh) Bcor和Zc3h12a在预防和治疗慢性感染中的用途
AU2010241483B2 (en) Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration
HK40075981A (en) Compositions including molecules of modified mrna and methods of using the same
Nguyen et al. Mesenchymal stem cell-based cancer gene therapy: Application and unresolved problems
Rippaus Development of a Haematopoietic Stem Cell-based Cell Therapy to Treat Brain Metastases
by Chimeric et al. GENE THERAPY OR THE NERVOUS SYSTEM I

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241220